Stock Alert for VIVUS Inc. (VVUS)
  • Stock Alert for VIVUS Inc. (VVUS)
  • Stock Alert for VIVUS Inc. (NASDAQ: VVUS)
  • " />

    Market Alert for Vivus Inc. (VVUS)

    VIVUS Inc. (Nasdaq: VVUS) is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, obstructive sleep apnea and sexual health.  Its lead product in clinical development, Qnexa, completed phase III clinical trials for the treatment of obesity and a New Drug Application (NDA) was filed and accepted by the Food and Drug Association (FDA). The Company received a Complete Response Letter (CRL) from the FDA and is preparing a written response to address the FDA’s requests for information included in the CRL. Qnexa is also in phase II clinical trials for type 2 diabetes and obstructive sleep apnea.  VVUS is also developing an erectile dysfunction drug, Avanafil, which is in phase III clinical trials.

    VVUS was founded in 1991 and is headquartered in Mountain View, California.

    Share Statistics (29-Nov-10) FY












    Symbol VVUS Revenue, $Mn 102.23 50.04 -51.0% 0.00 0.00
    Current price $6.46 Gross marg. 33.8% 34.3% 1.5%
    52wk Range: $4.69-$13.68 Oper. margin -13.0% -109.3% 740.8%
    Avg Vol (3m): 3,413,270 Net margin -9.7% -108.5%
    Market Cap. 524.58M
    Shares Outstanding EPS, $ -0.16 -0.75 368.8% -0.30 -0.22 -26.7%

    Source:, SEC Filings.

    Financial Summary

    Third-Quarter Results

    For the three months ended September 30, 2010, VVUS reported a net loss of $18 million, or $0.22 net loss per share, as compared to a net loss of $21.1 million, or $0.30 net loss per share, during the same period in 2009. The decrease in net loss in the second quarter of 2010 as compared to the second quarter of 2009 primarily results from the decrease in research and development spending due to the completion of the phase III clinical trials for Qnexa for the treatment of obesity, partially offset by increased general and administrative expenses, primarily due to Qnexa pre-commercialization activities in the third quarter of 2010.

    Nine Months Results

    For the nine months ended September 30, 2010, the Company reported a net loss of $59.6 million, or $0.74 net loss per share, as compared to a net loss of $41.1 million, or $0.59 net loss per share, during the same period in 2009. The increase in net loss in the nine months ended September 30, 2010, as compared to the nine months ended September 30, 2009, results from the completion of the recognition of the Evamist deferred revenue in 2009 and increased general and administrative expenses, primarily due to Qnexa pre-commercialization activities, partially offset by decreased research and development spending due to the completion of the pivotal phase III clinical trials for Qnexa for the treatment of obesity.

    Cash, Cash Equivalents and Available-for-Sale Securities

    VVUS had cash, cash equivalents and available-for-sale securities of $158.2 million at September 30, 2010, as compared to $206.8 million at December 31, 2009.  The decrease in cash, cash equivalents and available-for-sale securities of $48.6 million is primarily due to cash used in operations and other net cash uses offset by proceeds of $2.4 million from the exercise of common stock options and ESPP purchases.

    Source: VIVUS Inc.

    Financial Strength (Nov-29-2010) Company Industry Sector S&P 500
    Quick Ratio (MRQ) 8.24 2.34 2.24 0.68
    Current Ratio (MRQ) 8.33 2.93 2.83 1.01
    LT Debt to Equity (MRQ) 11.28 15.10 23.77 117.71
    Total Debt to Equity (MRQ) 11.28 17.74 28.43 170.95
    Interest Coverage (TTM) -19.57 0.18 1.28 19.18

    Source:, SEC Filings.

    Analyst Consensus

    This is the consensus forecast among 15 polled investment analysts. Against the Vivus Inc company.

    Analyst Detail Buy Outperform Hold Underperform Sell No Opinion
    Latest 3 4 4 2 2 0
    4 weeks ago 3 3 4 2 2 0
    2 months ago 3 1 6 2 2 0
    3 months ago 2 1 7 1 2 0
    Last year 3 3 4 0 0 0

    The 12 analysts offering 12-month price targets for VVUS have a median target of 11.00, with a high estimate of 16.00 and a low estimate of 2.00. The median estimate represents a 73.50% increase from the last price of 6.34.


    Consensus Estimates Analysis

    # of Estimates Mean High Low 1 Year Ago
    SALES (in millions)
    Quarter Ending Dec-10 6 7.45 8.70 4.90 8.43
    Quarter Ending Mar-11 2 1.46 2.80 0.12
    Year Ending Dec-10 15 9.90 19.10 4.37 27.16
    Year Ending Dec-11 10 27.42 60.00 0.50 56.64
    EARNINGS (per share)
    Quarter Ending Dec-10 16 -0.21 -0.07 -0.26 -0.20
    Quarter Ending Mar-11 4 -0.21 -0.13 -0.28
    Year Ending Dec-10 17 -0.94 -0.66 -1.04 -0.78
    Year Ending Dec-11 14 -0.77 -0.36 -1.15 -0.50
    LT Growth Rate (%) 1 53.50 53.50 53.50


    Investment Highlights

    VVUS late last month received a Complete Response Letter (CRL) from the FDA regarding the Qnexa NDA. The Company said the FDA declined to approve Qnexa and asked a detailed plan to evaluate and mitigate risks in women of childbearing potential.  The drug regulator also asked for evidence that the elevation in heart rate associated with phentermine/topiramate does not increase the risk for major adverse cardiovascular events. Qnexa suffered a setback three months prior when a panel of experts assembled by the FDA voted against the drug’s approval, citing side effects such as birth defects, depression and heart problems.

    “We remain confident in the efficacy and safety profile of Qnexa demonstrated in the clinical development program and look forward to continue working with the FDA towards the approval for the treatment of obesity,” said CEO Leland Wilson.

    The Company expects to complete its response to the FDA by the end of the year.

    About Qnexa

    Qnexa is an investigational drug being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which together decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase II and III clinical data to date, patients taking Qnexa have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

    During the third quarter, VVUS announced top-line results from a two-year study of Qnexa that showed significant and sustained weight loss of greater than 10% over two years. The Company reported that patients taking top- and mid-dose Qnexa achieved and maintained weight loss over two years of 11.4% and 10.4% of their initial body weight, respectively, as compared to placebo-treated patients with 2.5% weight loss (ITT-LOCF, p<0.0001). The findings come from the SEQUEL study (OB-305), a 52-week extension study for a subset of patients who completed the previously reported 56-week CONQUER study. The total study period was 108 weeks. SEQUEL included 675 obese or overweight patients, all of whom had two or more weight related co-morbidities, and an average baseline BMI of 36.1. Consistent with the first year experience, Qnexa therapy was well tolerated, with no new or unexpected adverse events. The most common side effects seen were constipation, tingling, dry mouth, altered taste and insomnia.


    Technical Analysis


    VVUS is below its 13-day moving average. This bearish sign is even more significant because the moving average is also trending lower.

    VVUS is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

    The MACD for VVUS currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of zero, which implies that the underlying moving averages are trending lower.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Nov29-2010 symbol Share, $ $ Mn 2010 2011 2010 2011
    Amylin Pharmaceuticals Inc. AMLN 12.98 1.87B n/a n/a 2.88 3.33
    Arena Pharmaceuticals Inc. ARNA 1.48 179.69M n/a n/a 10.55 8.43
    GlaxoSmithKline plc GSK 38.72 98.46B 13.04 10.06 2.16 2.18
    Eli Lilly & Co. LLY 33.89 37.45B 7.20 7.68 1.63 1.67
    Pfizer Inc. PFE 16.61 133.09B 7.48 7.25 1.98 2.01
    Orexigen Therapeutics Inc. OREX 5.56 264.56M n/a n/a n/a 6.61
    Abbott Laboratories ABT 46.60 72.03B 11.18 10.00 2.05 1.89
    Biotechnology Median 19.08 n/a 6.97 n/a
    VIVUS Inc. VVUS 6.46 524.56M n/a n/a 59.81 27.52

    Source: Thomson Financial

    Insider Trading Activity


    Inside Purchases – Last 6 Months

    Shares Transaction
    Purchases n/a 0
    Sales 84,250 3
    Net Shares Purchased (Sold) (84,250) 3
    Total Insider Shares Held 3.81M n/a
    % Net Shares Purchased (Sold) (2.2%) n/a
    Net Institutional Purchases — Prior Qtr to Latest Qtr
    Net Shares Purchased (Sold) (14,466,300)
    % Change in Institutional Shares Held (49.64%)

    Source: Yahoo Finance

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *